FTC Proposes Order to Resolve Anticompetitive Practices and Protect Healthcare Consumers
Author: Amy Asubonteng June 26, 2026 HRRC supports both the press release and the call to action given by the Federal Trade Commission. As high prices limit accessibility to quality healthcare…
Read the full articleYou might also wanna read
FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Proposed FTC order requires divestiture of four drug products to resolve anticompetitive concerns The Federal Trade Commission took action t
FTC Files Amicus Brief to Protect Consumers from Pharmaceutical Monopolies
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Johnson & Johnson illegally maintain
Free Market Groups, Advocates Oppose Codification of Most-Favored-Nation Drug Pricing
February 12th, 2026 The Honorable Members United States Congress Washington, D.C. 20515 RE: Coalition Opposing the Codification of Most-Favo

FTC Proposes Policy Statement Targeting AI Accuracy and Deceptive Practices, Seeks Public Comment
The Federal Trade Commission is seeking public comment on a

FTC Proposes Policy Statement Targeting AI Accuracy and Deceptive Practices, Seeks Public Comment
The Federal Trade Commission is seeking public comment on a
Antitrust Agency Insights: Developments at the U.S. Antitrust Enforcement Agencies — First Quarter 2026
In the first quarter of 2026, the U.S. antitrust agencies, the U.S. Department of Justice, Antitrust Division (DOJ), and the Federal Trade C
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade

Comments
Sign in to join the conversation.
No comments yet. Be the first.